GSK, Singapore BTI Collaborate On Vaccine Development
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Singapore's Bioprocessing Technology Institute and GlaxoSmithKline Biologicals SA Belgium reached an agreement in late January to collaborate on three vaccine and adjuvant-related research projects
You may also be interested in...
Singapore’s A*Star Scouts Indian Partners To Sharpen R&D Edge
An A*Star research arm held discussions with an India company interested in cell expression capabilities.
As Pfizer-Wyeth Combine Eye Vaccines Business, Novartis, GSK, Sanofi-Aventis And Indian Companies Brace For The Challenge
MUMBAI - These may be early days for Pfizer and Wyeth to analyze growth strategies of their vaccines business in emerging markets like India, but existing players like GlaxoSmithKline, Merck, Novartis and a host of home-grown companies like Panacea Biotec, Serum Institute and Shantha Biotech already seem well positioned to accelerate their growth in the quickly emerging vaccines market
GSK India Managing Director Hasit Joshipura On What Lies Ahead For India’s Largest Multinational Drug Company: An Interview With PharmAsia News (Part 2 of 2)
GlaxoSmithKline India Managing Director Hasit Joshipura is known as one of the most aggressive multinational pharma directors in India in terms of expansion strategy. Some top GSK officials say he was brought in at the helm with the task of making GSK sharper in its marketing approach. Joshipura presented those capabilities in his earlier stint as the managing director at Johnson & Johnson India. Joshipura sat down with PharmAsia News' India bureau to discuss what lies ahead for India's largest multinational drug company.